BindingDB logo
myBDB logout

64 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28098449 48 Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.EBI Universidade de Lisboa
28045524 38 Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.EBI Lexicon Pharmaceuticals
27075813 49 N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors.EBI National Health Research Institutes
27020685 4 Synthetic approaches to the 2014 new drugs.EBI Pfizer Inc.
25650254 1 Transporter-mediated tissue targeting of therapeutic molecules in drug discovery.EBI Lilly China Research and Development Center (LCRDC)
24842618 56 The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.EBI AMRI
24556379 34 Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors.EBI CSIR-Indian Institute of Chemical Technology
24456245 24 Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes.EBI Fudan University
24900773 14 Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes.EBI Mitsubishi Tanabe Pharma Corporation
24071445 30 Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.EBI National Taiwan University
23999047 9 N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.EBI Mitsubishi Tanabe Pharma Corporation
23809172 9 C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.EBI Mitsubishi Tanabe Pharma Corporation
23651509 13 Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.EBI Astellas Pharmaceutical Inc.
23273606 64 Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-ylß-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1).EBI Kissei Pharmaceutical Company
22889351 40 Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.EBI Chugai Pharmaceutical Co., Ltd.
23062824 72 Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-ylß-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.EBI Kissei Pharmaceutical Company
22818040 26 Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.EBI National Health Research Institutes
22652255 50 C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.EBI Chugai Pharmaceutical Co. Ltd
22507206 21 Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.EBI Astellas Pharma Inc.
21128592 51 Discovery of novel N--D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.EBI Taiwan National Health Research Institutes
20181486 51 Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners.EBI Green Cross Corporation
19785435 58 Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.EBI Princ
19243175 13 Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.EBI Bristol-Myers Squibb Co
21906953 34 Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.EBI Green Cross Corporation
21868239 15 Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.EBI Green Cross Corporation
21737266 43 C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.EBI Chinese Academy of Sciences
21090651 21 Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening.EBI National Health Research Institutes
21514014 45 Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.EBI Green Cross Corporation Research Center
21565497 38 Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors.EBI Amgen Inc.
21398124 62 Discovery of non-glucoside SGLT2 inhibitors.EBI Amgen Inc.
24900297 47 Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 InhibitorsEBI TBA
21193308 24 Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2.EBI Green Cross Corporation
20952196 20 Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.EBI Green Cross Corporation
20690635 12 Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.EBI Mitsubishi Tanabe Pharma Corporation
20637636 18 Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors.EBI Green Cross Corporation
20576578 36 ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.EBI Chinese Academy of Sciences
20434909 41 Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners.EBI Green Cross Corporation
20192242 4 Gneyulins A and B, stilbene trimers, and noidesols A and B, dihydroflavonol-C-glucosides, from the bark of Gnetum gnemonoides.EBI Hoshi University
20302302 40 (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.EBI Taisho Pharmaceutical Co., Ltd.
20149653 36 C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.EBI Pfizer Global Research& Development
20189404 28 Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter.EBI Hoshi University
19896374 53 Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.EBI Chinese Academy of Sciences
19700318 6 O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.EBI Chinese Academy of Sciences
18755586 32 Design and synthesis of fluorescent SGLT2 inhibitors.EBI Pfizer Global Research and Development
18707880 18 Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.EBI Princ
17374486 6 Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens.EBI Nippon Suisan Kaisha, Ltd
16380256 35 Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.EBI Johnson & Johnson Pharmaceutical Research and Development
16198559 17 Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.EBI Johnson & Johnson Pharmaceutical Research and Development
15380212 46 Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors.EBI Johnson & Johnson Pharmaceutical Research and Development
20063996 12 Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.BDB University of Karachi
28035796 2 Structural Insights into the Inhibition of Tubulin by the Antitumor Agent 4-(1,2,4-triazol-3-ylthio)-4-deoxypodophyllotoxin.BDB Huazhong Agricultural University
7490733 59 Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.BDB Boehringer Ingelheim Pharmaceuticals Inc.